HOLOGIC, INC. (NASDAQ:HOLX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
|
Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
“Company”) elected Amy M. Wendell as a director of the Company,
effective December 14, 2016. Ms. Wendell has over 30 years of
experience in the healthcare industry and was Senior Vice President
of Strategy and Business Development for Covidien plc until its
acquisition by Medtronic in 2015. Ms. Wendell is currently a Senior
Advisor to Perella Weinberg Partners Healthcare Investment Banking
Practice and McKinseys Strategy and Corporate Finance Practice and
also serves as a member of McKinsey’s Transactions Advisory Board.
Companys 2017 Annual Meeting of Stockholders, has been appointed to
serve on the Audit and Finance Committee of the Board of Directors.
As a non-employee director of the Company, Ms. Wendell will receive
compensation as described in the Director Compensation section of
the Companys 2016 Proxy Statement, except that she received a
pro-rated annual equity grant rather than a one-time sign-on equity
grant.
Wendell is filed with this Current Report on Form 8-K as Exhibit
99.1.
|
|
Item 9.01
|
Financial Statements and Exhibits
|
|
|
|
|
|
Exhibit Number
|
|
Description
|
|
99.1
|
|
Press Release dated December 16, 2016.
|
About HOLOGIC, INC. (NASDAQ:HOLX)
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems. HOLOGIC, INC. (NASDAQ:HOLX) Recent Trading Information
HOLOGIC, INC. (NASDAQ:HOLX) closed its last trading session down -0.01 at 40.08 with 2,254,593 shares trading hands.